- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.68 Å
- Oligo State
- hetero-1-1-1-1-1-1-1-1-1-1-1-1-1-mer
- Ligands
- 2 x HEA: HEME-A(Non-covalent)
- 1 x CU: COPPER (II) ION(Non-covalent)
- 1 x MG: MAGNESIUM ION(Non-covalent)
- 1 x NA: SODIUM ION(Non-functional Binders)
- 1 x CMO: CARBON MONOXIDE(Non-functional Binders)
- 5 x PGV: (1R)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PALMITOYLOXY)METHYL]ETHYL (11E)-OCTADEC-11-ENOATE(Non-covalent)
PGV.7: 14 residues within 4Å:- Chain A: N.406, T.408, W.409
- Chain D: T.77, A.81, F.84
- Chain K: F.4, H.5
- Chain M: P.12, Q.15, A.16, L.19
- Ligands: DMU.81, EDO.89
17 PLIP interactions:4 interactions with chain A, 5 interactions with chain K, 3 interactions with chain M, 5 interactions with chain D- Hydrophobic interactions: A:T.408, A:W.409, K:F.4, K:F.4, K:F.4, M:P.12, M:Q.15, M:L.19, D:T.77, D:A.81, D:F.84, D:F.84, D:F.84
- Hydrogen bonds: A:T.408
- Water bridges: A:N.406, K:F.4
- Salt bridges: K:H.5
PGV.8: 28 residues within 4Å:- Chain A: F.94, P.95, R.96, M.97, F.148, H.151, I.158, P.200
- Chain C: H.7, V.9, G.18, A.22, T.26, N.48, T.51, M.52, W.55, W.56, V.59, E.62, H.69, L.77, G.80, F.84, S.87, E.88
- Ligands: PEK.34, PGV.36
18 PLIP interactions:7 interactions with chain A, 11 interactions with chain C- Hydrophobic interactions: A:F.148, A:I.158, A:P.200, C:A.22, C:T.26, C:T.51, C:W.55, C:W.55, C:W.55, C:W.56, C:F.84, C:F.84
- Hydrogen bonds: A:R.96, A:R.96, A:M.97, C:W.55
- Salt bridges: A:R.96
- Water bridges: C:M.81
PGV.36: 23 residues within 4Å:- Chain C: M.49, M.52, W.56, V.59, I.60, S.63, T.64, H.69, M.81, F.84, H.205, I.208, F.212, R.219, H.224, F.225, T.226, H.229, H.230, F.231, G.232
- Ligands: PGV.8, CDL.38
28 PLIP interactions:26 interactions with chain C, 2 interactions with chain F- Hydrophobic interactions: C:W.56, C:W.56, C:W.56, C:W.56, C:W.56, C:W.56, C:I.60, C:F.84, C:F.84, C:I.208, C:I.208, C:I.208, C:F.212, C:F.212, C:F.212
- Hydrogen bonds: C:S.63, C:R.219, C:F.231, C:G.232
- Water bridges: C:S.63, C:R.219, C:H.229, C:H.229, F:Q.12, F:E.17
- Salt bridges: C:R.219, C:R.219, C:H.229
PGV.37: 13 residues within 4Å:- Chain A: F.237, D.298
- Chain C: T.93, W.97, Y.100, H.101, L.104, A.105
- Chain H: F.14, N.18, R.21
- Ligands: EDO.14, CHD.33
6 PLIP interactions:2 interactions with chain H, 3 interactions with chain C, 1 interactions with chain A- Water bridges: H:N.18, H:R.21
- Hydrophobic interactions: C:W.97, C:W.97, A:F.237
- Salt bridges: C:H.101
PGV.67: 2 residues within 4Å:- Chain C: W.256
- Chain G: A.1
1 PLIP interactions:1 interactions with chain C- Hydrophobic interactions: C:W.256
- 52 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.9: 7 residues within 4Å:- Chain A: Y.260, Y.261, V.394, H.395, P.398, W.494
- Chain M: I.1
Ligand excluded by PLIPEDO.10: 8 residues within 4Å:- Chain A: L.483, T.484, V.485, T.488, W.494, G.497, C.498
- Chain D: Y.8
Ligand excluded by PLIPEDO.11: 9 residues within 4Å:- Chain A: R.5, N.11, K.13, D.14, W.81, P.499, P.500, Y.502
- Chain L: N.9
Ligand excluded by PLIPEDO.12: 5 residues within 4Å:- Chain A: G.269, M.271, G.272
- Chain B: A.58, E.62
Ligand excluded by PLIPEDO.13: 1 residues within 4Å:- Ligands: TGL.82
Ligand excluded by PLIPEDO.14: 3 residues within 4Å:- Chain A: Y.304
- Ligands: CHD.33, PGV.37
Ligand excluded by PLIPEDO.15: 6 residues within 4Å:- Chain A: E.507
- Chain C: T.3
- Chain F: P.30, N.32, P.50, S.51
Ligand excluded by PLIPEDO.16: 3 residues within 4Å:- Chain A: L.136, A.137
- Chain B: Q.103
Ligand excluded by PLIPEDO.17: 7 residues within 4Å:- Chain A: Y.19, M.71, P.72, S.101, L.105, S.156, S.157
Ligand excluded by PLIPEDO.18: 6 residues within 4Å:- Chain A: H.256, T.259, K.265, T.490, N.491
- Ligands: EDO.59
Ligand excluded by PLIPEDO.19: 3 residues within 4Å:- Chain A: P.131, D.221, P.222
Ligand excluded by PLIPEDO.20: 7 residues within 4Å:- Chain A: K.265, E.266
- Chain B: T.55
- Chain F: N.66, T.68, I.70, S.84
Ligand excluded by PLIPEDO.21: 5 residues within 4Å:- Chain A: K.265, T.489
- Chain F: I.70, P.83
- Ligands: EDO.63
Ligand excluded by PLIPEDO.22: 7 residues within 4Å:- Chain A: M.390, H.413, M.417, A.464, V.465, M.468
- Ligands: HEA.1
Ligand excluded by PLIPEDO.27: 7 residues within 4Å:- Chain A: Y.447
- Chain B: M.1, A.2, Q.10, L.136, P.166, Y.193
Ligand excluded by PLIPEDO.28: 3 residues within 4Å:- Chain B: H.102, E.157, D.158
Ligand excluded by PLIPEDO.29: 3 residues within 4Å:- Chain B: E.157, P.176
- Ligands: EDO.41
Ligand excluded by PLIPEDO.30: 3 residues within 4Å:- Chain B: Y.40
- Chain I: A.24, V.27
Ligand excluded by PLIPEDO.31: 3 residues within 4Å:- Chain B: T.125, R.134, F.206
Ligand excluded by PLIPEDO.32: 4 residues within 4Å:- Chain B: W.104, Y.121, N.203, F.206
Ligand excluded by PLIPEDO.41: 7 residues within 4Å:- Chain A: P.222, A.223
- Chain B: G.177
- Chain C: E.109
- Chain H: W.62
- Ligands: EDO.29, EDO.44
Ligand excluded by PLIPEDO.42: 8 residues within 4Å:- Chain C: W.144, S.148, D.153, H.156
- Chain F: A.1
- Chain G: A.13, R.14, R.17
Ligand excluded by PLIPEDO.43: 2 residues within 4Å:- Chain A: W.103
- Chain J: L.40
Ligand excluded by PLIPEDO.44: 5 residues within 4Å:- Chain B: G.177
- Chain C: E.109
- Chain H: W.62, W.66
- Ligands: EDO.41
Ligand excluded by PLIPEDO.45: 4 residues within 4Å:- Chain C: H.1, Q.2, H.68
- Chain F: L.16
Ligand excluded by PLIPEDO.46: 3 residues within 4Å:- Chain C: Q.66
- Chain F: G.15
- Chain J: Q.13
Ligand excluded by PLIPEDO.47: 4 residues within 4Å:- Chain C: T.143, H.146, H.147
- Chain G: W.16
Ligand excluded by PLIPEDO.48: 1 residues within 4Å:- Chain C: F.249
Ligand excluded by PLIPEDO.49: 4 residues within 4Å:- Chain C: G.139, T.143, H.241
- Chain G: W.16
Ligand excluded by PLIPEDO.50: 5 residues within 4Å:- Chain D: P.22, V.24, A.25, K.60
- Chain E: R.26
Ligand excluded by PLIPEDO.51: 3 residues within 4Å:- Chain A: I.332, W.334
- Ligands: TGL.26
Ligand excluded by PLIPEDO.52: 7 residues within 4Å:- Chain D: Y.19, D.23
- Chain E: W.23, R.26, K.27, N.30
- Chain F: P.83
Ligand excluded by PLIPEDO.53: 7 residues within 4Å:- Chain A: T.488, L.495
- Chain D: Y.8, A.9, L.10, S.12
- Chain F: W.73
Ligand excluded by PLIPEDO.54: 6 residues within 4Å:- Chain D: W.45, S.46, L.48, I.50, K.53
- Ligands: EDO.57
Ligand excluded by PLIPEDO.55: 3 residues within 4Å:- Chain E: Y.14, K.17, E.24
Ligand excluded by PLIPEDO.56: 3 residues within 4Å:- Chain E: R.49, R.52, R.53
Ligand excluded by PLIPEDO.57: 7 residues within 4Å:- Chain D: K.53
- Chain E: L.89, N.90, G.93, I.94, S.95
- Ligands: EDO.54
Ligand excluded by PLIPEDO.59: 7 residues within 4Å:- Chain A: T.489, T.490
- Chain F: S.67, T.68, V.69, W.71
- Ligands: EDO.18
Ligand excluded by PLIPEDO.60: 3 residues within 4Å:- Chain C: H.229
- Chain F: D.9, E.17
Ligand excluded by PLIPEDO.61: 6 residues within 4Å:- Chain A: Y.510
- Chain F: P.36, K.37, T.39, N.47, L.48
Ligand excluded by PLIPEDO.62: 5 residues within 4Å:- Chain D: P.11
- Chain F: F.72, Q.80, R.81, P.83
Ligand excluded by PLIPEDO.63: 5 residues within 4Å:- Chain D: R.16, Y.19
- Chain E: T.31
- Chain F: P.83
- Ligands: EDO.21
Ligand excluded by PLIPEDO.68: 6 residues within 4Å:- Chain C: G.118
- Chain G: A.46, F.47, I.48, L.53, R.54
Ligand excluded by PLIPEDO.69: 5 residues within 4Å:- Chain G: G.10, G.12, A.13, R.14, T.15
Ligand excluded by PLIPEDO.71: 3 residues within 4Å:- Chain I: Q.70, S.71, K.73
Ligand excluded by PLIPEDO.74: 5 residues within 4Å:- Chain C: N.10, P.11
- Chain J: G.17, L.18, P.19
Ligand excluded by PLIPEDO.75: 2 residues within 4Å:- Chain J: K.10, Q.13
Ligand excluded by PLIPEDO.84: 5 residues within 4Å:- Chain L: G.7, K.8, I.10, F.12, S.13
Ligand excluded by PLIPEDO.86: 2 residues within 4Å:- Chain M: H.36
- Ligands: DMU.85
Ligand excluded by PLIPEDO.87: 4 residues within 4Å:- Chain L: R.40
- Chain M: W.32, H.36, Y.40
Ligand excluded by PLIPEDO.88: 6 residues within 4Å:- Chain A: T.46, L.47
- Chain D: V.100
- Chain M: L.37, D.38, K.41
Ligand excluded by PLIPEDO.89: 5 residues within 4Å:- Chain A: T.404, D.407
- Chain M: I.1, A.3
- Ligands: PGV.7
Ligand excluded by PLIP- 3 x TGL: TRISTEAROYLGLYCEROL(Non-covalent)
TGL.23: 16 residues within 4Å:- Chain A: F.346, V.350, Y.379, N.422, F.426, H.429, F.430, L.433
- Chain B: L.7, G.8, L.28, F.32, S.35, S.36, L.39
- Chain I: R.43
13 PLIP interactions:7 interactions with chain A, 1 interactions with chain I, 5 interactions with chain B- Hydrophobic interactions: A:F.346, A:F.426, A:F.426, A:F.426, A:F.426, A:H.429, A:F.430, B:F.32, B:F.32, B:L.39
- Salt bridges: I:R.43, B:H.24
- Water bridges: B:F.9
TGL.26: 24 residues within 4Å:- Chain A: W.334, M.339, L.342, G.343, K.411, F.414, A.415, F.418, V.419
- Chain B: L.39, I.42, T.47, K.49
- Chain D: R.70, S.71, T.72, E.74, W.75, V.78, M.83, I.86
- Chain I: R.16
- Ligands: EDO.51, DMU.79
14 PLIP interactions:4 interactions with chain D, 8 interactions with chain A, 2 interactions with chain B- Hydrophobic interactions: D:V.78, D:I.86, A:W.334, A:W.334, A:L.342, A:F.414, A:A.415, A:F.418, A:V.419, B:L.39, B:I.42
- Hydrogen bonds: D:W.75
- Water bridges: D:T.72
- Salt bridges: A:K.411
TGL.82: 26 residues within 4Å:- Chain A: F.2, T.17, L.18, L.20, L.21, F.22, W.25, P.106, L.110, L.113, F.393, F.400, S.401, I.472
- Chain L: N.9, I.10, P.11, F.12, S.13, R.19, M.23, F.27, F.28, S.30
- Ligands: EDO.13, DMU.83
17 PLIP interactions:10 interactions with chain A, 7 interactions with chain L- Hydrophobic interactions: A:T.17, A:L.18, A:L.20, A:F.22, A:F.22, A:W.25, A:W.25, A:P.106, A:F.393, A:I.472, L:I.10, L:F.12, L:F.12, L:F.27, L:F.27, L:F.28, L:F.28
- 1 x CUA: DINUCLEAR COPPER ION(Non-covalent)
- 1 x PSC: (7R,17E,20E)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSA-17,20-DIEN-1-AMINIUM 4-OXIDE(Non-covalent)
PSC.25: 22 residues within 4Å:- Chain A: F.321, H.328
- Chain B: I.41, M.45, H.52, M.56, D.57, E.60, V.61, I.64, W.65, L.68, P.69, I.72
- Chain E: T.3, D.4, F.7, D.36, L.37
- Chain I: R.10, A.14, L.17
17 PLIP interactions:3 interactions with chain I, 2 interactions with chain A, 10 interactions with chain B, 2 interactions with chain E- Hydrophobic interactions: I:A.14, I:L.17, A:F.321, A:F.321, B:I.41, B:I.41, B:M.56, B:V.61, B:I.64, B:L.68, B:P.69, B:I.72
- Water bridges: I:A.14
- Hydrogen bonds: B:E.60
- Salt bridges: B:H.52, E:D.4
- pi-Cation interactions: E:F.7
- 4 x CHD: CHOLIC ACID(Non-covalent)
CHD.33: 10 residues within 4Å:- Chain A: H.233, W.288, D.300, T.301, Y.304, F.305
- Chain C: W.97, H.101
- Ligands: EDO.14, PGV.37
9 PLIP interactions:6 interactions with chain A, 3 interactions with chain C- Hydrophobic interactions: A:W.288, A:Y.304, A:F.305, C:W.97
- Hydrogen bonds: A:T.301, C:W.97
- Water bridges: A:T.301
- Salt bridges: A:H.233, C:H.101
CHD.66: 6 residues within 4Å:- Chain G: R.14, R.17, F.18, F.21, G.22
- Ligands: PEK.35
5 PLIP interactions:5 interactions with chain G- Hydrophobic interactions: G:F.21
- Water bridges: G:R.17, G:R.17
- Salt bridges: G:R.14, G:R.17
CHD.72: 6 residues within 4Å:- Chain C: R.154, L.158, F.162, F.217, L.221
- Chain J: F.1
8 PLIP interactions:7 interactions with chain C, 1 interactions with chain J- Hydrophobic interactions: C:L.158, C:L.158, C:F.162, C:F.162, C:F.217, C:L.221
- Salt bridges: C:R.154
- Hydrogen bonds: J:F.1
CHD.73: 6 residues within 4Å:- Chain A: I.3
- Chain J: Y.32, R.33, M.36, T.37, L.40
3 PLIP interactions:2 interactions with chain J, 1 interactions with chain A- Hydrophobic interactions: J:R.33, J:T.37, A:I.3
- 2 x PEK: (1S)-2-{[(2-AMINOETHOXY)(HYDROXY)PHOSPHORYL]OXY}-1-[(STEAROYLOXY)METHYL]ETHYL (5E,8E,11E,14E)-ICOSA-5,8,11,14-TETRAENOATE(Non-covalent)
PEK.34: 22 residues within 4Å:- Chain A: H.151, T.207, L.210, L.215
- Chain C: W.32, Y.179, Y.180, A.182, F.184, T.185, I.186, F.196, G.200, F.201
- Chain G: W.62, T.68, F.69, F.70, H.71, N.76
- Ligands: PGV.8, DMU.65
17 PLIP interactions:5 interactions with chain C, 10 interactions with chain G, 2 interactions with chain A- Hydrophobic interactions: C:W.32, C:I.186, C:F.201, C:F.201, G:W.62, G:F.69, G:F.69, A:L.210, A:L.215
- Hydrogen bonds: C:I.186, G:T.68, G:F.70, G:F.70, G:N.76, G:N.76
- Water bridges: G:F.69, G:F.69
PEK.35: 15 residues within 4Å:- Chain C: K.155, H.156, Q.159, I.163, T.166, L.167, Y.170
- Chain F: A.1
- Chain G: R.17, F.21, G.22, L.25, P.26
- Ligands: CDL.64, CHD.66
16 PLIP interactions:10 interactions with chain C, 4 interactions with chain G, 2 interactions with chain F- Hydrophobic interactions: C:I.163, C:T.166, C:L.167, C:Y.170, C:Y.170, C:Y.170, G:F.21, G:L.25, G:P.26
- Hydrogen bonds: C:K.155, C:H.156, F:A.1
- Water bridges: C:Q.159, F:G.3
- Salt bridges: C:H.156, G:R.17
- 2 x CDL: CARDIOLIPIN(Non-covalent)
CDL.38: 20 residues within 4Å:- Chain C: T.46, M.49, L.50, Y.53, W.56, R.57, I.60, F.65, V.169, T.211, I.214, V.215, F.218, R.219, K.222, H.224
- Chain J: K.8, T.27, L.31
- Ligands: PGV.36
15 PLIP interactions:13 interactions with chain C, 2 interactions with chain J- Hydrophobic interactions: C:W.56, C:W.56, C:R.57, C:V.169, C:V.169, C:I.214, C:I.214, C:V.215, C:F.218, J:L.31
- Hydrogen bonds: C:Y.53
- Salt bridges: C:K.222, C:K.222, C:H.224, J:K.8
CDL.64: 20 residues within 4Å:- Chain C: N.123, L.125, L.129, T.132, S.133, L.136, V.140, L.248, Y.251, V.252, W.256
- Chain G: L.23, S.27, L.30, C.31, L.33, N.34, L.37, H.38
- Ligands: PEK.35
17 PLIP interactions:9 interactions with chain C, 8 interactions with chain G- Hydrophobic interactions: C:L.129, C:T.132, C:L.136, C:V.140, C:L.248, C:Y.251, C:V.252, C:W.256, G:L.23, G:L.30, G:L.30, G:L.33, G:L.37
- Hydrogen bonds: C:N.123, G:N.34
- Salt bridges: G:H.38, G:H.38
- 12 x DMU: DECYL-BETA-D-MALTOPYRANOSIDE(Non-covalent)(Non-functional Binders)
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.68 Å
- Oligo State
- hetero-1-1-1-1-1-1-1-1-1-1-1-1-1-mer
- Ligands
- 2 x HEA: HEME-A(Non-covalent)
- 1 x CU: COPPER (II) ION(Non-covalent)
- 1 x MG: MAGNESIUM ION(Non-covalent)
- 1 x NA: SODIUM ION(Non-functional Binders)
- 1 x CMO: CARBON MONOXIDE(Non-functional Binders)
- 5 x PGV: (1R)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PALMITOYLOXY)METHYL]ETHYL (11E)-OCTADEC-11-ENOATE(Non-covalent)
- 52 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 3 x TGL: TRISTEAROYLGLYCEROL(Non-covalent)
- 1 x CUA: DINUCLEAR COPPER ION(Non-covalent)
- 1 x PSC: (7R,17E,20E)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSA-17,20-DIEN-1-AMINIUM 4-OXIDE(Non-covalent)
- 4 x CHD: CHOLIC ACID(Non-covalent)
- 2 x PEK: (1S)-2-{[(2-AMINOETHOXY)(HYDROXY)PHOSPHORYL]OXY}-1-[(STEAROYLOXY)METHYL]ETHYL (5E,8E,11E,14E)-ICOSA-5,8,11,14-TETRAENOATE(Non-covalent)
- 2 x CDL: CARDIOLIPIN(Non-covalent)
- 12 x DMU: DECYL-BETA-D-MALTOPYRANOSIDE(Non-covalent)(Non-functional Binders)